N,N'-dimethylethylenediamine-N,N'-dipropionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N'-dimethylethylenediamine-N,N'-dipropionic acid
• 英文别名: 3-[2-[2-Carboxyethyl(methyl)amino]ethyl-methylamino]propanoic acid
• 化学式: C₁₀H₂₀N₂O₄
• 分子量: 232.28
• InChiKey: XYAWQRGITVQKII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.3
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N,N'-dimethylethylenediamine-N,N'-dipropionic acid 在 亚磷酸 、 三氯化磷 、 水 作用下， 以 氯苯 为溶剂， 反应 6.0h， 以28%的产率得到
  参考文献：
  名称：

  Synthesis and cytotoxicity of N,N′-dibisphosphonate ethylenediamine derivatives and platinum(II) complexes with high binding property to hydroxyapatite

  摘要：

  A series of N,N '-dibisphosphonate ethylenediamine derivatives (L1-L6) and their corresponding dichloroplatinum(II) complexes (1-6) have been prepared and characterized by elemental analysis, H-1 NMR, C-13 NMR, P-31 NMR, and HRMS spectra. The in vitro antitumor of compounds L1-L6 and 1-6 was tested by WST-8 assay with Cell Counting Kit-8, indicating that platinum-based complexes 1-6 showed higher cytotoxic efficacy than platinum-free compounds L1-L6 against SKOV3 and MG-63, especially complex 2 (R = CH3, n = 2) with comparable cytotoxicity to cisplatin after 72 h incubation. And complexes 1-6 were highly selective in cytotoxicity against MG-63 tumor cells than hFOB 1.19 normal cells. The in vitro hydroxyapatite binding test revealed that complexes 1 and 2 showed higher affinity (K ' = 4.2 and 3.5, respectively) for bone hydroxyapatite than cisplatin (K ' < 0.1) and zoledronate (K ' = 2.8). On basis of flow cytometry results, complex 2 induced cell death by apoptosis effect similar to cisplatin, different from zoledronate. Representative complex 2 has been proved to be a promising bone-targeting antitumor agent for subsequent in vivo study. (C) 2016 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2016.12.006
• 作为产物：
  描述：

  3,6-Diaza-3,6-dimethyl-1,8-octanedicarboxylic acid dimethyl ester 在 甲醇 、 sodium hydroxide 作用下， 生成 N,N'-dimethylethylenediamine-N,N'-dipropionic acid
  参考文献：
  名称：

  [EN] IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY
  [FR] LIPIDES IONISABLES ET COMPOSITIONS POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES

  摘要：

  The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

  公开号：

  WO2022218295A1

文献信息

• [EN] COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES<br/>[FR] COMPOSITIONS CONTENANT DES DÉRIVÉS DE DOLASTATINE LIÉS À DES ACIDES AMINÉS NON NATUREL
  申请人：AMBRX INC

  公开号：WO2012166560A1

  公开（公告）日：2012-12-06

  Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

  披露的是非天然氨基酸和杜洛司他汀类似物，其中包括至少一种非天然氨基酸，以及制造这种非天然氨基酸和多肽的方法。杜洛司他汀类似物可以包括广泛的可能性功能，但通常至少具有一个肟、羰基、二羰基和/或羟基胺基团。还披露了在翻译后进一步修改的非天然氨基酸杜洛司他汀类似物，实施这种修改的方法，以及纯化这种杜洛司他汀类似物的方法。通常，修改后的杜洛司他汀类似物至少包括一个肟、羰基、二羰基和/或羟基胺基团。进一步披露了使用这样的非天然氨基酸杜洛司他汀类似物和修改后的非天然氨基酸杜洛司他汀类似物的方法，包括治疗、诊断和其他生物技术应用。
• Photochemistry of Cobalt(III) Complexes. I. Optically Active Cobalt(III) Complexes Containing Co–C Bond Prepared by Photodecarboxylation of Amino Carboxylato Complexes
  作者：Hiroshi Kawaguchi、Miyuki Yoshida、Toshiaki Yonemura、Tomoharu Ama、Ken-ichi Okamoto、Takaji Yasui

  DOI：10.1246/bcsj.68.874

  日期：1995.3

  Some cobalt(III) complexes with Co–C σ-bond have been prepared by photodecarboxylation reactions of the complexes containing ethylenediamine-N,N′-dipropionate (eddp) or its analogs. The crystal structure of α-[Co(Me2eedmp-C,N,N′,O)(en)]+ (Me2eedmp: −CH2CH2N(CH3)(CH2)2N(CH3)(CH2)2COO−), which is the photolysis product of α-[Co(Me2eddp)(en)]+ (Me2eddp: CH2N(CH3)(CH2)2COO−}2), was determined by the X-ray

  通过含有乙二胺-N，N'-二丙酸酯（eddp）或其类似物的配合物的光脱羧反应制备了一些具有Co-Cσ键的钴（III）配合物。α-[Co(Me2eedmp-C,N,N',O)(en)]+ (Me2eedmp: −CH2CH2N(CH3)(CH2)2N(CH3)(CH2)2COO−)的晶体结构，即α-[Co(Me2eddp)(en)]+ (Me2eddp: CH2N(CH3)(CH2)2COO-}2) 的光解产物通过 X 射线衍射法测定。晶体为单斜晶系，空间群P21/n，a = 9.013(2), b = 13.420(1), c = 14.754(4) A, β = 92.75(1)°, V = 1782.5(6) A3, Z = 4，R = 0.038。与通常的 Co-O 键相比，C 原子与 Co 中心的配位导致位于 C 原子转位的 Co-O 键的伸长。旋光异构体的光解产物(Λ-α, Λ-β(1)
• Resin composition comprising water-soluble polyamide and vinyl alcohol-based polymer
  申请人：UNITIKA LTD.

  公开号：EP0039226A2

  公开（公告）日：1981-11-04

  A resin composition is described consisting essentially of from 0.5 to 100 parts by weight of a water-soluble polyamide and from 0.5 to 100 parts by weight of a vinyl alcohol-based polymer. The resin composition has excellent transparency and can be used, for example, to form light-sensitive resin compositions and adhesives.

  所述树脂组合物主要由 0.5 至 100 重量份的水溶性聚酰胺和 0.5 至 100 重量份的乙烯醇基聚合物组成。 该树脂组合物具有极佳的透明度，可用于制造光敏树脂组合物和粘合剂等。
• COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
  申请人：Ambrx, Inc.

  公开号：EP3470413A2

  公开（公告）日：2019-04-17

  Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

  本文公开了包括至少一种非天然氨基酸的非天然氨基酸和多拉他汀类似物，以及制造这种非天然氨基酸和多肽的方法。多拉他汀类似物可包括多种可能的官能团，但通常具有至少一个肟基、羰基、二羰基和/或羟胺基团。本文还公开了经翻译后进一步修饰的非天然氨基酸多拉他汀类似物、进行此类修饰的方法以及纯化此类多拉他汀类似物的方法。通常，修饰的多拉他汀类似物包括至少一个肟基、羰基、二羰基和/或羟胺基团。进一步公开的是使用此类非天然氨基酸多拉他汀类似物和修饰的非天然氨基酸多拉他汀类似物的方法，包括治疗、诊断和其它生物技术用途。
• Anti-CD70 antibody drug conjugates
  申请人：Ambrx, Inc.

  公开号：US10208123B2

  公开（公告）日：2019-02-19

  This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

  本发明涉及包含至少一个非天然编码氨基酸的抗 CD70 抗体和抗体药物共轭物。本发明公开了含有一个或多个非天然编码氨基酸的αCD70抗体，并进一步公开了抗体药物共轭物，其中本发明的αCD70抗体与一种或多种毒素共轭。进一步公开了使用这种非天然氨基酸抗体药物共轭物的方法，包括治疗、诊断和其他生物技术用途。